ArticleScientific reports2025
TRIM21 knockdown alleviates hemorrhage induced hepatic ischemia reperfusion injury by suppressing ferroptosis-induced NETs.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Neutrophil extracellular traps in liver diseases: from molecular mechanisms to therapeutic interventions.Acta pharmacologica Sinica · 2026Review
- Review
- Ferroptosis in Low-Density Neutrophils of Tuberculosis Patients Suppresses Bactericidal Function.Clinical and experimental pharmacology & physiology · 2026Article
- The emerging role of neutrophil extracellular traps in liver diseases: a narrative review.Medical molecular morphology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Hemorrhage-induced hepatic ischemia/reperfusion (I/R) injury is a severe complication of hemorrhagic shock, yet its molecular mechanisms remain unclear. The aim of this study was to investigate the potential mechanism of action of TRIM21 on hemorrhage-induced hepatic I/R injury. The role of TRIM21 in hepatic I/R injury was evaluated by establishing a mouse model of hemorrhage-induced hepatic I/R injury and an in vitro simulated oxygen-glucose deprivation/reoxygenation (OGD/R) hepatocyte injury model. A comprehensive analysis was conducted, including histopathological changes, serum biochemical indicators, inflammatory cytokine levels, markers of neutrophil extracellular trap (NETs) formation, and biomarkers related to ferroptosis, such as the expression of iron metabolism-related proteins SLC7A11 and FTH1, oxidative stress and antioxidant capacity, NETs formation markers (Cit-H3, PAD4, and MPO), and the expression levels of TRIM21.The study revealed that ferroptosis-induced NETs was involved in the process of hepatic I/R injury, concurrent with elevated serum ALT and AST levels and increased cell apoptosis. In the hemorrhage-induced hepatic I/R injury mouse model and OGD/R-induced hepatocyte injury, the expression of TRIM21 is significantly upregulated. Knockdown of TRIM21 can effectively inhibit the formation of ferroptosis-induced NETs, thereby alleviating hepatic I/R injury. In terms of the underlying mechanism, TRIM21 promotes the formation of ferroptosis-induced NETs by regulating the stability of the SLC7A11 protein, thus exacerbating hepatic I/R injury. The study discovered that silencing TRIM21 inhibits ferroptosis-mediated NETs formation by ubiquitinating SLC7A11, effectively alleviating hepatic I/R injury. This discovery may provide a potential therapeutic strategy for the treatment of hemorrhage-induced hepatic I/R injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.